

Dr. Reddy's Laboratories Ltd. 8-2-337, Road No. 3, Banjara Hills, Hyderabad - 500 034, Telangana,

CIN: L85195TG1984PLC004507

Tel:+91 40 4900 2900 Fax:+91 40 4900 2999 Email:mail@drreddys.com www.drreddys.com

September 8, 2017

Corporate Relationship Department BSE Limited
Dalal Street, Fort
Mumbai – 400 001

Fax Nos.: 022-22723121 / 22723719

National Stock Exchange of India Ltd. "Exchange Plaza" Bandra-Kurla Complex, Bandra (East), Mumbai – 400 051

Fax Nos.: 022-26598120/ 26598237

Scrip Code: 500124 Scrip Code: DRREDDY-EQ

Dear Sirs,

Sub: Intimation

This is to inform you that on 7th September, 2017, the Regulatory Authority of Germany (Regierung von Oberbayern), concluded an audit of our Formulations manufacturing facility in Duvvada, Vishakapatnam, with zero critical and six major observations. Products manufactured at the Facility are not currently exported to the EU. The company will be submitting a Corrective and Preventive Action plan (CAPA) to the authorities. The auditor has cautioned that the facility will receive EU-GMP certification from the Regulator upto November 2018 only when the Regulator approves the CAPA. The Facility's compliance with the CAPA and other applicable regulations will be reviewed again by the Regulator by the November 2018 for continuation of the Facility's EU-GMP certification.

This is for your information and record.

With regards,

Vi kalealellacueaf Vikas Sabharwal

Assistant Company Secretary

Encl: As above

CC:- New York Stock Exchange Inc.(Stock Code: RDY)